Trejo L.J., Titone S., Spencer K.M., Ruigt G.S.F. , Ereshefsky L. , Rosipal R. , English B.A. , Donello J.E., Killion B.

Quantitative electroencephalograms and event-related potentials as biomarkers in central nervous system drug development

Frontiers in Pharmacology, 17:1982607, 2026. doi:10.3389/fphar.2026.1982607.


Quantitative electroencephalography and event-related potentials are scalable

translational biomarkers of the pharmacodynamic effects of drugs acting in the

central nervous system. This review synthesizes evidence for resting-state

quantitative electroencephalography, sensory-evoked responses, and

endogenous event-related potentials across major central nervous system drug

classes, including antidepressants, antiseizure medications, antipsychotics,

cannabinoids, cholinergic modulators, N-methyl-D-aspartate (NMDA) receptor

modulators, psychedelics, sedatives, stimulants, and selected mixed-mechanism

agents. Across classes, drug effects are most interpretable when spectral power

is separated into periodic and aperiodic activity, and when resting-state

measures are integrated with event-related biomarkers such as mismatch

negativity, auditory steady-state response, sensory gating, and P300. The

evidence supports several mechanistic principles: γ- and δ-subunit-containing

GABAA modulation generate distinct electrophysiological profiles; NMDA receptor

antagonism dissociates spontaneous from evoked gamma band activity;

cholinergic tone produces bidirectional and pharmacologically transparent effects

on cortical desynchronization and sensory gating; and catecholaminergic,

serotonergic, sedative, and antiseizure agents converge on several non-specific

band-power changes. These convergences limit the interpretability of biomarkers

and support the use of prespecified multi-feature panels that combine spectral,

aperiodic, connectivity, and event-related measures. We conclude with practical

recommendations for early-phase clinical trials, including time-matched

baselines, control of vigilance and eye condition, pharmacokinetic-

pharmacodynamic sampling, standardized acquisition, and statistical analysis

plans suitable for biomarker qualification.